UBS maintains USD 172.00 target for Insmed stock

Published on 10/15/2026 at 22:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insmed reports results on October 29, 2026. Insmed stock costs EUR 88.44 on October 15, 2026 at 10:21 p.m. CEST at Lang & Schwarz.

Analyst view and earnings date

UBS kept its USD 172.00 price target for Insmed on October 12, 2026.
Insmed will publish third-quarter results on October 29, 2026.
Insmed stock costs EUR 88.44 at Lang & Schwarz on October 15, 2026 at 10:21 p.m. CEST.
Market capitalization stood at USD 21.7 billion on October 15, 2026.

INSM, US4576693075, Illustration mit AI erstellt.

UBS maintained a Buy rating and a USD 172.00 price target for Insmed on October 12, 2026, according to Investing.com. Against the USD 99.21 Nasdaq price on October 15, 2026, that target stood 73.38 percent higher. Insmed stock was trading at EUR 88.44 at Lang & Schwarz on October 15, 2026 at 10:21 p.m. CEST.

Target gap remains wide

The UBS target is one of several recent analyst reference points for Insmed. MarketBeat reported on October 14, 2026 that HC Wainwright maintained a Buy rating and a USD 220.00 target while raising its third-quarter 2026 earnings-per-share estimate to a loss of USD 0.13 from a loss of USD 0.31.

October 29 sets the next date

Insmed is scheduled to release its third-quarter 2026 results on October 29, 2026. The company reported second-quarter revenue of USD 425.49 million, compared with USD 395.50 million in analyst estimates, while adjusted earnings per share came to a loss of USD 0.06. StockTitan carried the company release dated October 5, 2026, which also reaffirmed full-year 2026 revenue guidance of USD 1.25 billion to USD 1.40 billion for BRINSUPRI and USD 450.00 million to USD 470.00 million for ARIKAYCE.

Price position and valuation

The Nasdaq quote last stood at USD 99.21 on October 15, 2026 at 4:00 p.m. ET. The session range was USD 97.90 to USD 100.72, while volume reached 3,346,151 shares against an average of 2,587,912, or 29.31 percent higher. The 52-week range was USD 90.39 to USD 212.75, placing the stock 9.76 percent above its low and 53.37 percent below its high.

Insmed had a market capitalization of USD 21.7 billion on October 15, 2026, and a price-to-earnings ratio of minus 24.14. The company operates in healthcare biotechnology and is developing therapies for serious and rare diseases, including BRINSUPRI, ARIKAYCE and the TPIP program.

Market context for Insmed

Insmed stock combines a USD 21.7 billion valuation with a broad 52-week range and a scheduled results date less than two weeks away. The upcoming report will give investors a fresh operating checkpoint after second-quarter revenue reached USD 425.49 million.